These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28059953)

  • 1. Lipoprotein(a): new insights from modern genomics.
    Afshar M; Thanassoulis G
    Curr Opin Lipidol; 2017 Apr; 28(2):170-176. PubMed ID: 28059953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
    Hung MY; Tsimikas S
    Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
    Tsimikas S
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic agents to lower lipoprotein (a) levels.
    Kolski B; Tsimikas S
    Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) and Cardiovascular Diseases　- Revisited.
    Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
    Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest developments in the treatment of lipoprotein (a).
    Bos S; Yayha R; van Lennep JE
    Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    Melita H; Manolis AA; Manolis TA; Manolis AS
    J Cardiovasc Pharmacol; 2022 Jan; 79(1):e18-e35. PubMed ID: 34694242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
    Fras Z
    Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
    Tsimikas S
    J Am Coll Cardiol; 2017 Feb; 69(6):692-711. PubMed ID: 28183512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The re-emergence of lipoprotein(a) in a broader clinical arena.
    Tsimikas S
    Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein (a): gene genie.
    Durrington PN; Schofield JD; Siahmansur T; Soran H
    Curr Opin Lipidol; 2014 Aug; 25(4):289-96. PubMed ID: 24977982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
    Tsushima T; Tsushima Y; Sullivan C; Hatipoglu B
    Endocr Pract; 2023 Jun; 29(6):491-497. PubMed ID: 36563785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.
    Rawther T; Tabet F
    J Mol Cell Cardiol; 2019 Jun; 131():1-11. PubMed ID: 30986377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
    Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
    Tsimikas S; Hall JL
    J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Antisense Therapies Targeting Lipoprotein(a).
    Plakogiannis R; Sorbera M; Fischetti B; Chen M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.
    Handhle A; Viljoen A; Wierzbicki AS
    Vasc Health Risk Manag; 2021; 17():527-542. PubMed ID: 34526771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When should we measure lipoprotein (a)?
    Kostner KM; März W; Kostner GM
    Eur Heart J; 2013 Nov; 34(42):3268-76. PubMed ID: 23735860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent.
    Hardy J; Niman S; Goldfaden RF; Ashchi M; Bisharat M; Huston J; Hartmann H; Choksi R
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):47-54. PubMed ID: 34490591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.